1. Home
  2. Labeler Index
  3. Novartis Pharmaceuticals Corporation
  4. 0078-1000
  5. Product Images: Leqvio

Product Images Leqvio

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Leqvio NDC 0078-1000 by Novartis Pharmaceuticals Corporation, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

molecular formula of inclisiran sodium - leqvio 01

molecular formula of inclisiran sodium - leqvio 01

Figure 1: Mean Percent Change from Baseline in LDL-C Over 18 Months in Patients with ASCVD on Maximally Tolerated Statin Therapy (Study 1) - leqvio 02

Figure 1: Mean Percent Change from Baseline in LDL-C Over 18 Months in Patients with ASCVD on Maximally Tolerated Statin Therapy (Study 1) - leqvio 02

This appears to be a table showing the percent change from baseline in patients taking either "incisarian" or a placebo for the "ORION-10" study. The study appears to involve 70-75 patients taking the placebo and 61-78 patients taking the incisiran over a period of several months.*

Figure 2: Mean Percent Change from Baseline in LDL-C Over 18 Months in Patients with ASCVD on Maximally Tolerated Statin Therapy (Study 2) - leqvio 03

Figure 2: Mean Percent Change from Baseline in LDL-C Over 18 Months in Patients with ASCVD on Maximally Tolerated Statin Therapy (Study 2) - leqvio 03

This appears to be a chart or table showing the levels of DL cholesterol in a group of patients who were either given a placebo or the drug "Inciiran." The number of patients in each group is listed, along with their cholesterol levels. However, without more context it is difficult to provide a more detailed description or interpretation of the data.*

Figure 3: Mean Percent Change from Baseline in LDL-C Over 18 Months in Patients with HeFH on Maximally Tolerated Statin Therapy (Study 3) - leqvio 04

Figure 3: Mean Percent Change from Baseline in LDL-C Over 18 Months in Patients with HeFH on Maximally Tolerated Statin Therapy (Study 3) - leqvio 04

The text describes the change in LDL cholesterol levels in patients receiving a drug called inclisiran compared to a placebo over a period of time. The data is presented in a table showing the number of patients in each group.*

PRINCIPAL DISPLAY PANEL LEQVIO® (inclisiran) injection Contains One Single-dose Prefilled Syringe For subcutaneous use For administration by a healthcare professional only 284 mg/1.5 mL (189 mg/mL) NDC 0078-1000-60 Sterile Solution Rx only NOVARTIS - leqvio 05

PRINCIPAL DISPLAY PANEL LEQVIO® (inclisiran) injection Contains One Single-dose Prefilled Syringe For subcutaneous use For administration by a healthcare professional only 284 mg/1.5 mL (189 mg/mL) NDC 0078-1000-60 Sterile Solution Rx only NOVARTIS - leqvio 05

LEQVIO® (inclisiran) injection is used for subcutaneous administration and comes in a single-dose pre-filled syringe of 1.5 mL containing 284mg inclisiran. It may contain sodium hydroxide and/or phosphoric acid for pH adjustment. The recommended dosage should be referred to in the prescribing information. The storage guidelines are between 2°C and 8°C (36°F and 46°F), with excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. It should be discarded after single use. The product contains no preservatives or natural rubber latex. For further information, visit www.LEQVIO.com or call 1-858-669-6652. Note: quality not high.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.